Cultural Challenges of BlueBird Bio Expansion into Germany

BlueBird Bio is a biotechnology multinational corporation (MNC), with headquarters in Cambridge, Massachusetts, specializing in gene therapy solutions for autoimmune diseases and cancer. The company was recently approved, in Germany, for their new drug Zynteglo for the treatment of betta thalassemia...

Full description

Bibliographic Details
Main Author: Igor Ban
Format: Article
Language:English
Published: St. John's University, Tobin College of Business 2020-12-01
Series:Journal of Global Awareness
Subjects:
Online Access:https://doi.org/10.24073/jga/1/02/06
id doaj-ef82ba207f5c4ebdb1cb154a2c173d49
record_format Article
spelling doaj-ef82ba207f5c4ebdb1cb154a2c173d492021-03-31T02:48:35ZengSt. John's University, Tobin College of BusinessJournal of Global Awareness1932-08172020-12-011211110.24073/jga/1/02/06Cultural Challenges of BlueBird Bio Expansion into GermanyIgor Ban0St. John's UniversityBlueBird Bio is a biotechnology multinational corporation (MNC), with headquarters in Cambridge, Massachusetts, specializing in gene therapy solutions for autoimmune diseases and cancer. The company was recently approved, in Germany, for their new drug Zynteglo for the treatment of betta thalassemia. This approval opened the door for further investment in the European market, starting with the contracting of Apceth Biopharma and purchases of new land and equipment to establish a permanent residence in the country. The opening of the new European headquarters will demonstrate new challenges for BlueBird Bio, as cultural and institutional differences between the host country and parent country are quite distinctive. Some of the main differences among countries are their cultural dimensions in dealing with risk, masculinity, and indulgence. Unlike the United States, Germany is risk avert, values input of all in decision-making, and has a general attitude following the best practice approach. The US focuses on the individual dimension of a culture where employees are valued for their independence. Furthermore, the differences between governmental policies in the two countries vary strongly. The German government has strict policies on employee protection and can affect the decision making of the organization. There is also the presence of labor unions and collective bargaining; two aspects of organizational structure US-based companies are trying to avoid. BlueBird Bio is an emerging MNC, and its success depends upon its ability to recognize the differences in cultures and institutions between the countries. The company has already been exposed to multiple countries in Europe and has strong programs in employee education supplemented with strong company benefits for its employees, which is providing excellent groundwork for establishing headquarters in Germany.https://doi.org/10.24073/jga/1/02/06biotechnologycultural dimensionsfederal drug administrationhost country nationalhuman resource managementindividualismmultinational corporationsparent country nationalt-cells treatment
collection DOAJ
language English
format Article
sources DOAJ
author Igor Ban
spellingShingle Igor Ban
Cultural Challenges of BlueBird Bio Expansion into Germany
Journal of Global Awareness
biotechnology
cultural dimensions
federal drug administration
host country national
human resource management
individualism
multinational corporations
parent country national
t-cells treatment
author_facet Igor Ban
author_sort Igor Ban
title Cultural Challenges of BlueBird Bio Expansion into Germany
title_short Cultural Challenges of BlueBird Bio Expansion into Germany
title_full Cultural Challenges of BlueBird Bio Expansion into Germany
title_fullStr Cultural Challenges of BlueBird Bio Expansion into Germany
title_full_unstemmed Cultural Challenges of BlueBird Bio Expansion into Germany
title_sort cultural challenges of bluebird bio expansion into germany
publisher St. John's University, Tobin College of Business
series Journal of Global Awareness
issn 1932-0817
publishDate 2020-12-01
description BlueBird Bio is a biotechnology multinational corporation (MNC), with headquarters in Cambridge, Massachusetts, specializing in gene therapy solutions for autoimmune diseases and cancer. The company was recently approved, in Germany, for their new drug Zynteglo for the treatment of betta thalassemia. This approval opened the door for further investment in the European market, starting with the contracting of Apceth Biopharma and purchases of new land and equipment to establish a permanent residence in the country. The opening of the new European headquarters will demonstrate new challenges for BlueBird Bio, as cultural and institutional differences between the host country and parent country are quite distinctive. Some of the main differences among countries are their cultural dimensions in dealing with risk, masculinity, and indulgence. Unlike the United States, Germany is risk avert, values input of all in decision-making, and has a general attitude following the best practice approach. The US focuses on the individual dimension of a culture where employees are valued for their independence. Furthermore, the differences between governmental policies in the two countries vary strongly. The German government has strict policies on employee protection and can affect the decision making of the organization. There is also the presence of labor unions and collective bargaining; two aspects of organizational structure US-based companies are trying to avoid. BlueBird Bio is an emerging MNC, and its success depends upon its ability to recognize the differences in cultures and institutions between the countries. The company has already been exposed to multiple countries in Europe and has strong programs in employee education supplemented with strong company benefits for its employees, which is providing excellent groundwork for establishing headquarters in Germany.
topic biotechnology
cultural dimensions
federal drug administration
host country national
human resource management
individualism
multinational corporations
parent country national
t-cells treatment
url https://doi.org/10.24073/jga/1/02/06
work_keys_str_mv AT igorban culturalchallengesofbluebirdbioexpansionintogermany
_version_ 1724178667065573376